219 related articles for article (PubMed ID: 19968066)
1. [Prognosis and chromosomal abnormalities in 79 children with t (8;21) acute myeloid leukemia].
Chen YM; Liu TF; Ruan M; Zou Y; Chen XJ; Guo Y; Wang SC; Zhu XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):542-6. PubMed ID: 19968066
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
3. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].
Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240
[TBL] [Abstract][Full Text] [Related]
4. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
7. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
9. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
Schoch C; Haase D; Haferlach T; Gudat H; Büchner T; Freund M; Link H; Lengfelder E; Wandt H; Sauerland MC; Löffler H; Fonatsch C
Leukemia; 1996 Aug; 10(8):1288-95. PubMed ID: 8709633
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].
Li HY; Yue H; Wei XD; Zhu XH; Zhang YL; Zhang LN; Liu YY; Wang P; Fang BJ; Li YF; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):110-2. PubMed ID: 18681312
[TBL] [Abstract][Full Text] [Related]
13. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Frassoni F; Milpied N; Attal M; Blaise D; Meloni G; Iori AP; Michallet M; Willemze R; Deconninck E; Harousseau JL; Polge E; Rocha V
J Clin Oncol; 2008 Jul; 26(19):3183-8. PubMed ID: 18506024
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
15. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
16. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
Numata A; Fujimaki K; Aoshima T; Onizuka M; Hagihara M; Miyazaki K; Fujita H; Sakai R; Machida S; Tanaka E; Nakajima Y; Hattori Y; Tanaka M; Yamazaki E; Shirasugi Y; Inoue Y; Watanabe S; Fujisawa S
Rinsho Ketsueki; 2012 Jul; 53(7):698-704. PubMed ID: 22975772
[TBL] [Abstract][Full Text] [Related]
18. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
[TBL] [Abstract][Full Text] [Related]
19. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
